MXPA05012096A - Derivados de amina ciclica, procedimientos para su preparacion y composiciones farmaceuticas que los contienen. - Google Patents
Derivados de amina ciclica, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.Info
- Publication number
- MXPA05012096A MXPA05012096A MXPA05012096A MXPA05012096A MXPA05012096A MX PA05012096 A MXPA05012096 A MX PA05012096A MX PA05012096 A MXPA05012096 A MX PA05012096A MX PA05012096 A MXPA05012096 A MX PA05012096A MX PA05012096 A MXPA05012096 A MX PA05012096A
- Authority
- MX
- Mexico
- Prior art keywords
- processes
- preparation
- pharmaceutical compositions
- compositions containing
- cyclic amine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Un compuesto de formula (I) (ver formula (I)) en la que R representa un radical seleccionado de (ver formulas i), ii), iii), iv)) en el que R7 es halogeno, ciano, alquilo C1-4, alcoxi C1-4, triflurometilo o trifluorometoxi; p es un numero entero de 0 a 3; R1 representa hidrogeno, halogeno, ciano, alquenilo C2-4, alquilo C1-4 opcionalmente sustituido por halogeno, ciano o alcoxi C1-4; R2 representa hidrogeno o alquilo C1-4; R3 y R4 representan independientemente hidrogeno, alquilo C1-4 o R3 junto R4 representan cicloalquilo C3-7; R5 representa: fenilo sustituido por 1 a 3 grupos seleccionados independientemente de trifluorometilo, alquilo C1-4, ciano, alcoxi C1-4, trifluorometoxi, halogeno o (SO)r-alquilo(C1-4), naftilo sustituido por 1 a 3 grupos seleccionados independientemente de trifluorometilo, alquilo C1-4, ciano, alcoxi C1-4,, trifluorometoxi, halogeno o (SO)r-alquilo(C1-4), un grupo heterociclico biciclico condensado de 9 a 10 miembros sustituido por 1 a 3 grupos seleccionados independientemente de trifluorometilo, alquilo C1-4, ciano, alcoxi C1-4,, trifluorometoxi, halogeno o (SO)r-alquilo(C1-4) o R5 es un grupo heterociclico de 5 o 6 miembros sustituido por 1 a 3 grupos seleccionados independientemente de trifluorometilo, alquilo C1-4, ciano, alcoxi C1-4,, trifluorometoxi, halogeno o (SO)r-alquilo(C1-4); R6 representa hidrogeno o (CH2)qR8; R8 representa hidrogeno, cicloalquilo C3-7, alcoxi (C1-4), amina, alquil(C1-4), (alquil(C1-4))2-amina, OC(O)NR9R10 o C(O)NR9R10;R9 y R10 representan independientemente hidrogeno, alquilo C1-4 o cicloalquilo C3-7; m representa cero o 1; n es 1 o 2; q es un numero entero de 1 a 4; r es 1 o 2; con tal de que cuando R5 sea fenilo sustituido por 1 a 3 grupos seleccionados independientemente de trifuorometilo, alquilo C1-4, ciano, alcoxi C1-4, trifluorometoxi, halogeno o (SO)r-alquilo(C1-4); R no sea el radical i) (ver formula i)); o sus sales o solvatos farmaceuticamente aceptables; procedimientos para su preparacion como composiciones farmaceuticas que lo contienen y su uso en el tratamiento de condiciones mediadas por taquiquininas y/o por la inhibicion selectiva de la proteina transportadora de la reabsorcion de serotonina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0310724.0A GB0310724D0 (en) | 2003-05-09 | 2003-05-09 | Chemical compounds |
| PCT/EP2004/005005 WO2004099143A1 (en) | 2003-05-09 | 2004-05-07 | Cyclic amine derivatives, processes for their preparation, and pharmaceutical compositions containing them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05012096A true MXPA05012096A (es) | 2006-02-08 |
Family
ID=9957781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05012096A MXPA05012096A (es) | 2003-05-09 | 2004-05-07 | Derivados de amina ciclica, procedimientos para su preparacion y composiciones farmaceuticas que los contienen. |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20070073061A1 (es) |
| EP (1) | EP1622871A1 (es) |
| JP (1) | JP4684221B2 (es) |
| KR (1) | KR20060009313A (es) |
| CN (1) | CN100534983C (es) |
| AR (1) | AR044269A1 (es) |
| AU (1) | AU2004235967B2 (es) |
| BR (1) | BRPI0410154A (es) |
| CA (1) | CA2524894A1 (es) |
| EG (1) | EG24668A (es) |
| GB (1) | GB0310724D0 (es) |
| IS (1) | IS8164A (es) |
| MA (1) | MA27795A1 (es) |
| MX (1) | MXPA05012096A (es) |
| MY (1) | MY140027A (es) |
| NO (1) | NO20055835L (es) |
| NZ (1) | NZ543068A (es) |
| RU (1) | RU2392270C2 (es) |
| TW (1) | TWI332499B (es) |
| WO (1) | WO2004099143A1 (es) |
| ZA (1) | ZA200508339B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0412865D0 (en) | 2004-06-09 | 2004-07-14 | Glaxo Group Ltd | Chemical compounds |
| US7844037B2 (en) | 2005-08-08 | 2010-11-30 | Palm, Inc. | Method and device for enabling message responses to incoming phone calls |
| EP2094692B1 (en) * | 2006-11-01 | 2012-11-28 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, ap-1 and/or nf-kappab activity and use thereof |
| EP2331505A2 (en) * | 2008-09-01 | 2011-06-15 | NeuroSearch A/S | Piperidine-4-acetamide derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| ES2672099T3 (es) | 2011-07-04 | 2018-06-12 | Irbm - Science Park S.P.A. | Antagonistas del receptor NK-1 para el tratamiento de la neovascularización corneal |
| CN106187999A (zh) * | 2015-05-04 | 2016-12-07 | 复旦大学 | 取代哌啶类化合物及其制备方法和用途 |
| KR20240019754A (ko) | 2021-03-23 | 2024-02-14 | 바이오에이지 랩스, 인코포레이티드 | Nlrp3 인플라마좀의 억제제 |
| WO2023147468A1 (en) | 2022-01-28 | 2023-08-03 | BioAge Labs, Inc. | N-oxide inhibitors of nlrp3 inflammasome |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US309720A (en) * | 1884-12-23 | William p | ||
| NL262366A (es) * | 1960-03-14 | |||
| GB1356117A (en) * | 1970-12-16 | 1974-06-12 | Searle & Co | 1-3-cyano-3,3-diphenylpropyl-4-phenylpiperidine-4-carboxylic acid derivatives |
| US5635510A (en) * | 1993-05-06 | 1997-06-03 | Merrell Pharmaceuticals Inc. | Substituted pyrrolidin-3-yl-alkyl-piperidines |
| DE19603767A1 (de) * | 1996-02-02 | 1997-08-07 | Hoechst Ag | Pyrrolidinpropionsäurederivate mit bradykinin-antagonistischer Wirkung |
| US6020347A (en) * | 1997-11-18 | 2000-02-01 | Merck & Co., Inc. | 4-substituted-4-piperidine carboxamide derivatives |
| WO1999025685A1 (en) * | 1997-11-18 | 1999-05-27 | Merck & Co., Inc. | 4-substituted-4-piperidine carboxamide derivatives |
| US6423519B1 (en) * | 1998-07-15 | 2002-07-23 | Gpc Biotech Inc. | Compositions and methods for inhibiting fungal growth |
| CA2443672C (en) * | 2001-04-12 | 2011-03-29 | Pharmacopeia, Inc. | Aryl and biaryl piperidines used as mch antagonists |
| JP2005510563A (ja) * | 2001-11-26 | 2005-04-21 | シェーリング コーポレイション | 肥満およびｃｎｓ障害の処置のためのピペリジン系ｍｃｈアンタゴニスト |
| TW200403058A (en) * | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| US20060128752A1 (en) * | 2002-07-03 | 2006-06-15 | Giuseppe Alvaro | Chemical compounds |
-
2003
- 2003-05-09 GB GBGB0310724.0A patent/GB0310724D0/en not_active Ceased
-
2004
- 2004-05-07 MX MXPA05012096A patent/MXPA05012096A/es active IP Right Grant
- 2004-05-07 RU RU2005138315/04A patent/RU2392270C2/ru not_active IP Right Cessation
- 2004-05-07 TW TW093112840A patent/TWI332499B/zh not_active IP Right Cessation
- 2004-05-07 NZ NZ543068A patent/NZ543068A/xx unknown
- 2004-05-07 BR BRPI0410154-5A patent/BRPI0410154A/pt not_active IP Right Cessation
- 2004-05-07 JP JP2006505412A patent/JP4684221B2/ja not_active Expired - Fee Related
- 2004-05-07 EP EP04731635A patent/EP1622871A1/en not_active Withdrawn
- 2004-05-07 AU AU2004235967A patent/AU2004235967B2/en not_active Ceased
- 2004-05-07 CA CA002524894A patent/CA2524894A1/en not_active Abandoned
- 2004-05-07 AR ARP040101565A patent/AR044269A1/es not_active Application Discontinuation
- 2004-05-07 MY MYPI20041688A patent/MY140027A/en unknown
- 2004-05-07 CN CNB2004800194957A patent/CN100534983C/zh not_active Expired - Fee Related
- 2004-05-07 KR KR1020057021196A patent/KR20060009313A/ko active IP Right Grant
- 2004-05-07 WO PCT/EP2004/005005 patent/WO2004099143A1/en active Application Filing
- 2004-05-07 US US10/554,822 patent/US20070073061A1/en not_active Abandoned
-
2005
- 2005-10-14 ZA ZA200508339A patent/ZA200508339B/en unknown
- 2005-10-29 EG EGNA2005000691 patent/EG24668A/xx active
- 2005-11-08 MA MA28584A patent/MA27795A1/fr unknown
- 2005-12-01 IS IS8164A patent/IS8164A/is unknown
- 2005-12-08 NO NO20055835A patent/NO20055835L/no unknown
-
2007
- 2007-10-10 US US11/869,945 patent/US20090192194A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EG24668A (en) | 2010-04-11 |
| EP1622871A1 (en) | 2006-02-08 |
| US20090192194A1 (en) | 2009-07-30 |
| AU2004235967A1 (en) | 2004-11-18 |
| BRPI0410154A (pt) | 2006-05-16 |
| TW200510309A (en) | 2005-03-16 |
| RU2005138315A (ru) | 2007-06-20 |
| RU2392270C2 (ru) | 2010-06-20 |
| KR20060009313A (ko) | 2006-01-31 |
| US20070073061A1 (en) | 2007-03-29 |
| WO2004099143A1 (en) | 2004-11-18 |
| ZA200508339B (en) | 2006-10-25 |
| JP4684221B2 (ja) | 2011-05-18 |
| GB0310724D0 (en) | 2003-06-11 |
| JP2006525975A (ja) | 2006-11-16 |
| MY140027A (en) | 2009-11-30 |
| AR044269A1 (es) | 2005-09-07 |
| NZ543068A (en) | 2009-07-31 |
| CN1819995A (zh) | 2006-08-16 |
| MA27795A1 (fr) | 2006-03-01 |
| CN100534983C (zh) | 2009-09-02 |
| NO20055835L (no) | 2006-02-07 |
| AU2004235967B2 (en) | 2008-10-23 |
| IS8164A (is) | 2005-12-01 |
| TWI332499B (en) | 2010-11-01 |
| NO20055835D0 (no) | 2005-12-08 |
| CA2524894A1 (en) | 2004-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5721006A2 (es) | Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa | |
| AR068413A2 (es) | Derivados 8-amino, metodos de preparacion, composiciones farmaceuticas y su uso en terapia | |
| TW200633979A (en) | Method | |
| NO20055688L (no) | Organiske forbindelser | |
| EA200970585A1 (ru) | Бензамидные производные как агонисты ер-рецепторов | |
| MY140528A (en) | Spiroketal derivatives and their use as therapeutic agents for diabetes | |
| NO20072978L (no) | Nye betuinderivater, preparat derav og anvendelse derav | |
| NO20054135L (no) | Kipolinon/benzoksazin derivater og anvendelser derav | |
| EA200600811A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ | |
| DE60305484D1 (de) | Verbindungen und deren verwendung als 5-ht inhibitore | |
| NO20063597L (no) | Acetylinske piperazinforbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister | |
| CY1116183T1 (el) | Πιπεραζινοδιονες ως ανταγωνιστες υποδοχεα οξυτοκινης | |
| ATE372995T1 (de) | Benzo(b)(1,4)dioxepinderivate | |
| EA200601194A1 (ru) | Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором | |
| NO20062533L (no) | 5-fluor, 5-klor- og cyanopyridin-2-yl-tetrazoler som ligander for den metabotrofe glutamatreseptor-5 | |
| JO2413B1 (en) | Benzoxazine derivatives and their use | |
| ATE429429T1 (de) | Pharmazeutisches verfahren und damit hergestellte verbindungen | |
| MA27795A1 (fr) | Derives d'amine cycliques, procedes de preparation de ceux-ci et compositions pharmaceutiques les contenant | |
| NO20055749L (no) | Sulfamat benzotiofenderivater som steroid sulfatase inhibitorer | |
| ATE447575T1 (de) | Selektive spirocyclische glucocorticoid-rezeptor- modulatoren | |
| BR0318521A (pt) | arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados | |
| UY28688A1 (es) | Derivados de amida | |
| WO2004005256A3 (en) | Substituted 4-phenyl-piperidin-amides as tachykinin antagonists and serotonin reptake inhibitors | |
| NO20062307L (no) | Spirofuropyridinarylderivater | |
| ATE465151T1 (de) | 4-aryloxy-chinolin-derivate als 5-ht6-modulatoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |